The FDA has approved RoxyBond® (oxycodone hydrochloride) tablets for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
The following language is extracted from the RoxyBond product label:*
RoxyBond will be available in 5mg, 15mg and 30mg tablets, with a dosing range of every 4-6 hours as needed for pain.
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, RoxyBond should be reserved patients for whom alternative treatment options (e.g., non-opioid analgesics or non-opioid combination products):
- Have not been tolerated or are not expected to be tolerated
- Have not provided adequate analgesia or are not expected to provide adequate analgesia
*Information presented is from the product label and does not necessarily reflect Healthesystems’ recommendations for opioid prescribing.
For further information, read the FDA label or approval letter.